AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Neuroscience Portfolio by Year
Neuroscience Portfolio — Worldwide reported growth YoY (%) (%)
AbbVie Neuroscience Portfolio: 19.6% in FY2025, up 3.0 pts from a year earlier.
Latest, FY2025
19.6%
Period ended Dec 31, 2025
Change on a year earlier
+3.0 pts
16.6% in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Neuroscience | 9,340 | 1,427 | 10,767 | 18.1 | 30.7 | 19.6 | 29.3 | 19.4”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Neuroscience Portfolio — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19.6% | +3.0 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 16.6% | -1.6 pts | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 18.2% | +8.1 pts | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 10.1% | -59.4 pts | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 69.5% | – | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
Cite this data
StockData. (2026). AbbVie Neuroscience Portfolio (%), annual FY2021–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta-neuro-ww-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.